Lundbeck to trial migraine drug in young people

A new phase III trial in the US will investigate whether extending the patient target group of Lundbeck's drug Vyepti to include younger patients is possible.
Lundbeck's headquarters in Valby, Copenhagen | Photo: Lundbeck / PR
Lundbeck's headquarters in Valby, Copenhagen | Photo: Lundbeck / PR
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY CATHERINE BRETT

285 participants aged 12-17 will test Lundbeck's drug Vyepti as a preventative treatment for migraines over the next year.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading